td-6450
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02022306)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- td-6450
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02716428 | Phase 2 | May 1, 2016 | Auckland Clinical Studies, Southern California Research Center, Trek Therapeutics, PBC |
| NCT02593162 | Phase 2 | Oct 1, 2015 | Southern California Research Center, Trek Therapeutics, PBC |
| NCT02116543 | Phase 1 | May 1, 2014 | Theravance |
| NCT02022306 | Phase 1 | Feb 1, 2014 | Theravance |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Southern California Research Center | For profit | 2 | 0 | 1 | 2015 |
| Theravance | For profit | 2 | 2 | 1 | 2014 |
| Trek Therapeutics, PBC | For profit | 2 | 2 | 1 | 2015 |
| Auckland Clinical Studies | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1